Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of CLN-081 in EGFR exon 20 insertion NSCLC
NL-OMON59213Phase 2Active, not recruiting
- Sponsor
- Cullinan Pearl
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of zipalertinib, sponsored by Cullinan Pearl. Started Mar 2020; status: active, not recruiting.
02
Drugs
zipalertinib
Beyond the preview
Go deeper on NL-OMON59213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59213.